COVID-19

[Biomedicine & Pharmacotherapy] The authors provide an overview of the pathways involved with cardiomyocyte in COVID-19 subjects to help promoting pharmacotherapies that can protect against SARS-CoV-2-induced cardiac injuries.

[Nature News] Molnupiravir, one of two antiviral pills that have caused excitement in the past few months because preliminary clinical-trial results showed that they can significantly reduce hospitalizations and deaths from COVID-19, has yet to receive an emergency use authorization from the US FDA.

[American Journal of Respiratory and Critical Care Medicine] Alveolar and endothelial injury may be differentially associated with COVID-19 disease severity over time. The authors described alveolar and endothelial injury dynamics and associations with COVID-19 severity, cardiorenovascular injury, and outcomes.

[Cell Death Discovery] Researchers investigated species-specific cell susceptibility, virus dose-dependent infectivity, and infection kinetics, using primary human and porcine respiratory epithelial cells.

[Pfizer, Inc.] Pfizer, Inc. and BioNTech SE announced that the FDA has expanded the Emergency Use Authorization of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 16 years of age and older.

[Signal Transduction and Targeted Therapy] The authors combined analyses of immune cells and cytokine/chemokine networks with endothelial activation and injury.